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Abstract
Helicobacter pylori (HP) infection is endemic worldwide. The pro-
posed treatment is expensive and there are few reports regarding
reinfection rates in Brazil. The aim of this study was to compare the
eradication rates obtained with two therapeutic options and to evaluate
reinfection one year after treatment. This was a prospective random-
ized trial with 55 patients. Thirty-nine patients had active duodenal
ulcer (DU) and 16 non-ulcer dyspepsia (NUD), and all tested positive
for HP. Diagnosis was based on at least two positive tests: ultrarapid
urease test, histology and/or culture. Patients were randomized to two
groups: group OMC treated with 40 mg omeprazole (once a day), 500
mg metronidazole and 250 mg clarithromycin (twice daily) for 7 days,
or group NA treated with 300 mg nizatidine (once a day) and 1000 mg
amoxicillin (twice daily) for 14 days. Those patients in whom HP was
eradicated were followed up for one year to evaluate reinfection.
Twenty-five patients were randomized for OMC and 30 for NA. HP
eradication occurred in 20/25 patients (80%) treated with OMC and
13/30 (43%) treated with NA (P = 0.01). After reallocation because of
initial treatment failure, the overall eradication rate was 44/51 patients
(86%). After an average follow-up of one year, we evaluated 34
patients (23 with DU and 11 with NUD). Reinfection occurred in 3/34
patients (7.6%). We conclude that OMC is effective for HP eradica-
tion, and that NA should not be used. Reinfection occurs in 7.6% of
the patients in the first year after eradication.
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Since the first description of Helicobacter
pylori (HP) in gastric biopsies by Warren
and Marshall (1), interest in gastric bacteri-
ology was renewed. The infection is cur-
rently endemic worldwide with a high preva-
lence (up to 60%) in developing regions such
as South America, Africa and Asia (2-4).
Several pathogenic mechanisms have al-
ready been demonstrated (5). Infection is
associated with gastric mucosa inflamma-
tion, even in the absence of duodenal ulcer
(DU). Probably different responses depend
on interactions between the bacteria and host
factors (6). H. pylori infection causes chronic
gastritis, gastric and duodenal ulcer, prob-
ably gastric adenocarcinoma (7,8) and mu-
cosa-associated lymphoid tissue (9). The role
of HP in non-ulcer dyspepsia (NUD) is contro-
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versial. A variety of tests have been proposed
for infection diagnosis: urease test, histology,
culture and urea breathing test (10,11), all with
high sensitivity and specificity.
Therapeutic studies using bismuth, amox-
icillin and metronidazole have reported up to
90% effectiveness (6) but with the disadvan-
tage of poor patient compliance. Therapy with
amoxicillin associated with omeprazole was
reported to eradicate infection in more than
80% of patients, with lower side effect rates
and cost (12). The recurrence rate after HP
eradication in adult patients in Brazil is still
unknown. In developed countries, where preva-
lence is lower, recurrence ranges from 1 to 5%
one year after treatment (13).
The present study was a blind prospec-
tive randomized trial, performed between
March 1996 and April 1998, including pa-
tients referred to the Endoscopy Unit, Divi-
sion of Gastroenterology, UNIFESP-EPM,
because of dyspepsia. The study was ap-
proved by the Ethics Committee of Hospital
Sªo Paulo, UNIFESP-EPM. Written consent
was obtained from all patients.
Inclusion criteria were age between 18
and 70 years and at least two HP-positive
tests. Group 1 consisted of patients with
active DU and group 2 of NUD patients
(normal or nonerosive gastritis on endos-
copy, and normal abdominal ultrasound and
stool examination). Exclusion criteria were
severe chronic diseases that hindered the
proposed therapy, pregnancy and/or breast-
feeding, use of antibiotics, bismuth or non-
steroidal anti-inflammatory drugs in the 4
weeks preceding index endoscopy, and a
previous history of side effects to the drugs
proposed in the study. In the DU group we
excluded patients with gastric ulcer, neopla-
sia, previous gastric surgery or complicated
DU (bleeding or stricture). In the NUD group,
patients with diagnosed worm infestation or
ultrasound abnormalities (gallstones, bile
duct stones, pancreatic diseases), hiatus her-
nia, esophagitis, or erosive gastritis were
excluded.
The diagnosis of HP infection was based
on five antral biopsies, two for the ultrarapid
urease test (10), two for histology and one
for culture. Histology slides were stained
with Giemsa. One specimen was immedi-
ately placed on an HP-specific growth medi-
um. The plates were incubated under micro-
aerobiosis and examined after 4 to 7 days. H.
pylori infection was considered to be present
when at least two tests were positive and
absent when at least two tests were negative.
Table 1 shows sensitivity, specificity, posi-
tive and negative predictive values and accu-
racy for all tests.
Patients in the NUD group answered a
questionnaire to evaluate the frequency, in-
tensity and duration of five symptoms: epi-
gastric pain, night pain, gastric fullness, heart-
burn, and eructation, all graded as light,
moderate or severe.
We reported good results in eradicating
HP infection with amoxicillin monotherapy
(14). In an attempt to evaluate an easier and
cheaper therapeutic option, patients were
randomized to two treatment groups as fol-
lows: group OMC - 40 mg omeprazole (once
a day), 500 mg metronidazole and 250 mg
clarithromycin (twice daily) for 7 days; group
NA - 300 mg nizatidine (once a day) and
1000 mg amoxicillin (twice daily) for 14
days. All drugs were supplied free of charge.
Patients were instructed to bring back the
containers and medications for compliance
evaluation and did not receive any mainte-
nance treatment. Those who took less than
50% of the supplied drugs were considered
violators and excluded from the study and
statistical analysis. Clinical improvement,
ulcer healing and HP eradication were evalu-
ated blindly.
Follow-up consisted of clinical visits af-
ter 30 days, 6 months and 1 year or whenever
necessary. Endoscopy was performed 60 days
after the end of treatment to evaluate eradi-
cation and ulcer healing. Patients with eradi-
cated infection were followed up to one year
and then submitted to another endoscopy for
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evaluation of ulcer relapse and HP status.
Non-ulcer patients with failed eradication
were referred to our outpatient clinic. Ulcer
patients with failed eradication were crossed
over to the other therapeutic group and again
evaluated after 60 days by endoscopy and
HP tests. Patients whose infection was eradi-
cated were submitted to endoscopy one year
later. Those who were still HP carriers were
considered treatment failures and referred to
our outpatient clinic.
Sixty-two patients were included: 39 with
active DU (group 1) and 23 with NUD (group
2). Median age was 32.8 years (range from
18 to 66 years), with 27 men and 35 women.
Seven patients were excluded before ran-
domization: 6 did not show up for the second
clinical visit (to receive the drugs) and 1
patient had symptom worsening in the week
between the first endoscopy and randomiza-
tion. He came back to the Endoscopy Unit
and a second procedure revealed erosive
gastritis, probably secondary to nonsteroidal
anti-inflammatory drugs, and he was not
randomized.
The OMC group consisted of 25 patients
(19 with DU and 6 with NUD) and the NA
group consisted of 30 patients (20 with DU
and 10 with NUD). H. pylori eradication was
achieved in 20/24 patients (83%) with OMC
and in 13/30 patients (43%) with NA (P =
0.007). One patient was excluded because of
protocol violation. Based on an intention to
treat analysis, eradication occurred in 20/25
patients (80%) and 13/30 patients (43%) in
the OMC and NA groups, respectively (P =
0.01).
When ulcer and non-ulcer patients were
analyzed separately, OMC led to HP eradi-
cation in 83% of patients in both groups.
Among non-ulcer patients, only two reported
symptomatic improvement, two had no
changes and one patient reported worsening.
Treatment with NA led to HP eradication
in 7/20 (35%) DU and 6/10 (60%) NUD
patients. Thirteen patients with DU were
still infected after treatment: 11 were treated
with OMC and eradication was achieved in
9/11 patient (82%). Two patients were ex-
cluded at this point due to protocol violation.
Among the 6 patients with NUD in whom
HP was eradicated, there was symptomatic
improvement in 4, and symptoms remained
unchanged in 2. Table 2 and Figure 1 show
the results of HP eradication for all patients.
Overall, 36/39 patients (92%) with DU
obtained complete healing and 3 (8%) con-
tinued to have an active lesion and were
referred to our outpatient clinic. Symptom
scores improved in 6/11 patients (54%) with
NUD in whom HP was successfully treated.
Considering both treatment arms, HP infec-
tion was eradicated in 44/51 patients (84%)
in a per protocol analysis and 44/55 (80%)
if an intention to treat approach was consid-
ered.
Table 2. Helicobacter pylori (HP) eradication and ulcer healing after the first
treatment or after reallocation.
Treatment Group N HP eradication (PP) DU healing
Initial OMC DU (19) 15/18 (83%)a 17/19 (89%)
NUD (6) 5/6 (83%) -
Total (25) 20/24 (83%) 17/19 (89%)
NA DU (20) 7/20 (35%) 17/20 (85%)
NUD (10) 6/10 (60%) -
Total (30) 13/30 (43%) 17/20 (85%)
Reallocation OMC DU (13) 9/11 (82%)b 10/13 (77%)
NA DU (2) 2/2 (100%) 1/2 (50%)
aOne patient was excluded because of protocol violation; btwo patients
were excluded because of protocol violation. PP: per protocol analysis; DU:
duodenal ulcer; NUD: non-ulcer dyspepsia; OMC: omeprazole, metronida-
zole and clarithromycin; NA: nizatidine and amoxicillin; N: number of pa-
tients in each group.
Table 1. Results of tests for the diagnosis and therapy monitoring of
Helicobacter pylori infection.
Test S E PPV NPV AC
Urease 96.77 98.18 98.36 96.42 97.43
Culture 91.52 100.00 100.00 91.37 95.53
Histology 98.38 89.08 91.04 98.00 94.01
Data are reported as %. S = sensitivity; E = specificity; PPV = positive
predictive value; NPV = negative predictive value; AC = accuracy.
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One year after eradication (12.47 – 4.56
months) we were able to evaluate 34 patients
(23 DU and 11 NUD) for reinfection. The
reinfection rate was 7.6% (3/34 patients),
with all 3 patients being from the DU group.
All DU patients presented healed lesions at
the one-year control endoscopy, including
the 3 with reinfection.
In patients with peptic ulcer, the impor-
tance of bacterial eradication has been well
established, with reported high recurrence
rate in those who remain HP positive. In
Brazil, the cost of triple therapy and patient
compliance are major problems regarding
HP treatment. A previous study using ome-
prazole and amoxicillin to treat patients with
HP-associated ulcers demonstrated good
clinical results and high eradication rates
(12), but these results have not been repro-
duced in Brazil.
There is no consensus about the role of
HP in NUD. Functional dyspepsia is defined
as epigastric pain or chronic discomfort (15),
a definition including a series of symptoms
like pain, early satiety, nausea, anorexia,
heartburn, and regurgitation. Identification
of HP has led to speculation regarding its
correlation with functional dyspepsia and
therefore bacterial eradication would contri-
bute to clinical improvement in such pa-
tients. Several studies have produced contra-
dictory results. McCarthy et al. (16) studied
83 patients with functional dyspepsia and
HP and reported significantly impaired symp-
toms in untreated patients or those with rein-
fection.
The treatment used in our study (OMC)
showed an eradication rate of 83% in a per
protocol analysis and 80% in an intention to
treat approach. Side effects were minor and
no patient interrupted treatment because of
them. All patients excluded from the OMC
group were excluded due to protocol viola-
tion, denoting difficulty in dealing with the
large number of tablets, since the problem of
cost was eliminated. Previous use of amoxi-
cillin did not interfere with the response to
OMC: patients treated in this group after
failure of NA showed a similar eradication
rate (82%). Development of resistance to
amoxicillin is not common (13,17). The eradi-
cation of HP with a 7-day course of OMC
was similar to that obtained in 14-day thera-
peutic trials previously reported (18,19). In
Protocol
violation (1)
62 patients
Eradication (5)
Remained
infected (1)Eradication
(15)
OMC (25)
NUD (6)(19)DU
Remained
infected (3)
Remained
infected (13)
Reallocation (15)
Eradication (9)
Remained
infected (2)
OMC (13) NA (2)
Eradication (2)
Remained
infected (4)
Eradication (6)
NUD (10)
NA (30)
DU (20)
Eradication (7)
Protocol
violation (2)
1 patient
refused
reallocation
*
Figure 1. Flow chart of all pa-
tients. *From the 62 patients,
six were excluded before ran-
domization because they did not
show up for a clinical visit, and
one was excluded because his
symptoms worsened during the
week before randomization. For
abbreviations, see legend to
Table 2.
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our opinion, the 7-day treatment has some
advantages, namely lower cost and probably
better compliance, and most authors con-
sider it the best first choice.
Patients treated with NA for 14 days
presented a low eradication rate (43%), con-
firming that therapy with only one antibiotic
should not be prescribed. Among patients
treated with NA the eradication rate was
higher in the NUD group (60%) when com-
pared to the ulcer group (35%).
Among the 11 patients with NUD in
whom the infection was eradicated, 6/11
(55%) presented symptomatic improvement,
in 4/11 (36%) the symptoms were unchanged
and 1/11 (9%) presented clinical worsening.
Therefore, HP eradication was not associ-
ated with clinical improvement and the role
of reinfection was not assessed in this group
of patients.
The reinfection rate after one year was
7.6% in our study. This is higher than in
developed areas like the USA and Europe,
where reinfection rates range from 1 to 5%
(13), probably because of low socioeconomic
status. However, we should consider the loss
of patient follow-up in this phase of the
study. It is possible that, although already
higher than in other reports, this rate repre-
sents an underestimated value.
We conclude that 7-day treatment with
omeprazole, metronidazole and clarithromy-
cin is effective in the eradication of H. pylori
(83%). Although cheaper, monotherapy with
amoxicillin should not be used due to the
low eradication rate obtained. Reinfection
occurred in 7.6% of the patients after an
average follow-up of 12 months.
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